News
LUCD
0.4163
+9.15%
0.0349
Lucid Diagnostics Reports Third Quarter 2026 Financial Results
NASDAQ · 2h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12h ago
Lucid Diagnostics (LUCD) Q3 2026 Earnings Call Transcript
The Motley Fool · 17h ago
Lucid Diagnostics Reports Third-Quarter Results and Medicare Progress
TipRanks · 19h ago
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 20h ago
*Lucid Diagnostics 3Q EBITDA Loss $6.5M >LUCD
Dow Jones · 20h ago
*Lucid Diagnostics 3Q Rev $1.2M >LUCD
Dow Jones · 20h ago
*Lucid Diagnostics 3Q Loss/Shr 3c >LUCD
Dow Jones · 20h ago
Lucid Diagnostics Non-GAAP EPS of -$0.06 in-line, revenue of $1.21M misses by $0.43M
Seeking Alpha · 20h ago
Lucid Diagnostics Q3 Adj. EPS $(0.06), Inline, Sales $1.203M Miss $1.635M Estimate
Benzinga · 20h ago
Press Release: Lucid Diagnostics Provides -2-
Dow Jones · 20h ago
Orthofix (OFIX) Surpasses Q3 Earnings Estimates
NASDAQ · 3d ago
Weekly Report: what happened at LUCD last week (1102-1106)?
Weekly Report · 4d ago
PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes
Benzinga · 11/03 13:17
Weekly Report: what happened at LUCD last week (1026-1030)?
Weekly Report · 11/02 09:30
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/27 12:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/26 17:05
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Celcuity (CELC) and Lucid Diagnostics (LUCD)
TipRanks · 10/26 13:30
Weekly Report: what happened at LUCD last week (1019-1023)?
Weekly Report · 10/26 09:30
More
Webull provides a variety of real-time LUCD stock news. You can receive the latest news about Lucid Diagnostics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LUCD
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc.